GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aytu BioPharma Inc (NAS:AYTU) » Definitions » Pretax Margin %

AYTU (Aytu BioPharma) Pretax Margin % : 2.35% (As of Dec. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Aytu BioPharma Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Aytu BioPharma's Pre-Tax Income for the three months ended in Dec. 2024 was $0.38 Mil. Aytu BioPharma's Revenue for the three months ended in Dec. 2024 was $16.22 Mil. Therefore, Aytu BioPharma's pretax margin for the quarter that ended in Dec. 2024 was 2.35%.

The historical rank and industry rank for Aytu BioPharma's Pretax Margin % or its related term are showing as below:

AYTU' s Pretax Margin % Range Over the Past 10 Years
Min: -2956.87   Med: -195.5   Max: -6.81
Current: -6.81


AYTU's Pretax Margin % is ranked worse than
70.63% of 984 companies
in the Drug Manufacturers industry
Industry Median: 5.565 vs AYTU: -6.81

Aytu BioPharma Pretax Margin % Historical Data

The historical data trend for Aytu BioPharma's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aytu BioPharma Pretax Margin % Chart

Aytu BioPharma Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -49.29 -88.42 -112.64 -15.88 -17.38

Aytu BioPharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.46 -14.68 -21.82 9.04 2.35

Competitive Comparison of Aytu BioPharma's Pretax Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aytu BioPharma's Pretax Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Aytu BioPharma's Pretax Margin % falls into.



Aytu BioPharma Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Aytu BioPharma's Pretax Margin for the fiscal year that ended in Jun. 2024 is calculated as

Pretax Margin=Pre-Tax Income (A: Jun. 2024 )/Revenue (A: Jun. 2024 )
=-14.076/81.002
=-17.38 %

Aytu BioPharma's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=0.382/16.221
=2.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aytu BioPharma  (NAS:AYTU) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Aytu BioPharma Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Aytu BioPharma's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aytu BioPharma Business Description

Traded in Other Exchanges
Address
7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
Executives
Joshua R. Disbrow director, officer: Chief Executive Officer AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Christopher Brooke officer: Chief Operating Officer C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD CO 80112
Jarrett Disbrow officer: Chief Business Officer 373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD CO 80112
John Jr. Donofrio director C/O AYTU BIOSCIENCE, INC., 373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD CO 80112
Carl Dockery director P.O. BOX 2477, LAKELAND FL 33806-2477
Vivian H Liu director
Mark K Oki officer: Chief Financial Officer C/O ALEXZA PHARMACEUTICALS INC, 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Abhinav Jain director C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD CO 80112
Wilmot B. Harkey 10 percent owner C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Daniel Mack 10 percent owner C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Nantahala Capital Management, Llc 10 percent owner 130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840
Greg Pyszczymuka officer: Chief Commerical Officer C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD CO 80112
Richard I Eisenstadt officer: Chief Financial Officer 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Gerald W. Mclaughlin director 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Beth Hecht director C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050